The application to the European Medicines Agency (EMA) comes days after the companies applied for emergency use of their vaccine in the United States. They said their candidate, BNT162b2, could be launched in the European Union this month.
‘If EMA concludes that the benefits of the vaccine candidate outweigh its risks in protecting against Covid-19, it will recommend granting a CMA (conditional marketing authorization)that could potentially enable use of BNT162b2 in Europe before the end of 2020,’ they said in a joint statement.
An effective immunization is seen as the main weapon against the pandemic, which has claimed more than 1.4 million lives and ravaged economies across the globe. Close to 50 potential vaccines are being tested on volunteers worldwide.
US drugmaker Pfizer and Germany’s BioNTech reported final trial results on Nov. 18 that showed their vaccine candidate was 95% effective in preventing Covid-19, with no major safety concerns, raising the prospect of US and European approval as early as December.
Any clearance in the EU and United States will be ‘conditional’ or for ‘emergency use’, respectively, meaning developers are obliged to continue trials and provide more trial results as they emerge.
The European filing completes the so-called rolling review process, which was initiated with the EMA on Oct. 6.
The British government said last week that Pfizer and BioNTech had reported the data from their clinical trials to the Medicines and Healthcare products Regulatory Agency (MHRA).
On 4 February 2021, the 17th edition of the FIFA Club World Cup™ officially kicked off in Qatar, with…
118 Views | the publication reaches you by | Qatar TodayDo you have information you want to reach our readers?
You can subscribe to our Facebook, Twitter and Google pages or use our RSS feed channel to always read the most important news about Qatar, the Gulf and the world.